SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:5a8c4cad-e246-4d33-bed6-0c8d3f6a8444"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:5a8c4cad-e246-4d33-bed6-0c8d3f6a8444" > Apalutamide for Met...

  • Chi, Kim NVancouver Prostate Centre (författare)

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019
  • 12 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:5a8c4cad-e246-4d33-bed6-0c8d3f6a8444
  • https://lup.lub.lu.se/record/5a8c4cad-e246-4d33-bed6-0c8d3f6a8444URI
  • https://doi.org/10.1056/NEJMoa1903307DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • BACKGROUND: Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined.METHODS: In this double-blind, phase 3 trial, we randomly assigned patients with metastatic, castration-sensitive prostate cancer to receive apalutamide (240 mg per day) or placebo, added to ADT. Previous treatment for localized disease and previous docetaxel therapy were allowed. The primary end points were radiographic progression-free survival and overall survival.RESULTS: A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The median age was 68 years. A total of 16.4% of the patients had undergone prostatectomy or received radiotherapy for localized disease, and 10.7% had received previous docetaxel therapy; 62.7% had high-volume disease, and 37.3% had low-volume disease. At the first interim analysis, with a median of 22.7 months of follow-up, the percentage of patients with radiographic progression-free survival at 24 months was 68.2% in the apalutamide group and 47.5% in the placebo group (hazard ratio for radiographic progression or death, 0.48; 95% confidence interval [CI], 0.39 to 0.60; P<0.001). Overall survival at 24 months was also greater with apalutamide than with placebo (82.4% in the apalutamide group vs. 73.5% in the placebo group; hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005). The frequency of grade 3 or 4 adverse events was 42.2% in the apalutamide group and 40.8% in the placebo group; rash was more common in the apalutamide group.CONCLUSIONS: In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups. (Funded by Janssen Research and Development; TITAN ClinicalTrials.gov number, NCT02489318.).

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Agarwal, NeerajHuntsman Cancer Institute,University of Utah (författare)
  • Bjartell, AndersLund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urological cancer, Malmö,Lund University Research Groups,Skåne University Hospital(Swepub:lu)kir-abj (författare)
  • Chung, Byung HaYonsei University (författare)
  • Pereira de Santana Gomes, Andrea JLiga Norte Riograndense Contra o Câncer (författare)
  • Given, RobertEastern Virginia Medical School (författare)
  • Juárez Soto, ÁlvaroHospital Universitario de Jerez de la Frontera (författare)
  • Merseburger, Axel SUniversity Medical Center Schleswig-Holstein (författare)
  • Özgüroğlu, MustafaIstanbul University (författare)
  • Uemura, HirotsuguKindai University Hospital (författare)
  • Ye, DingweiFudan University Shanghai Cancer Center (FUSCC) (författare)
  • Deprince, KrisJanssen Pharmaceuticals, US (författare)
  • Naini, VahidJanssen Pharmaceuticals, US (författare)
  • Li, JinhuiJanssen Pharmaceuticals, US (författare)
  • Cheng, ShintaJanssen Pharmaceuticals, US (författare)
  • Yu, Margaret KJanssen Pharmaceuticals, US (författare)
  • Zhang, KeJanssen Pharmaceuticals, US (författare)
  • Larsen, Julie SJanssen Pharmaceuticals, US (författare)
  • McCarthy, SharonJanssen Pharmaceuticals, US (författare)
  • Chowdhury, SimonSarah Cannon Research Institute,St Thomas' Hospital (författare)
  • Vancouver Prostate CentreHuntsman Cancer Institute (creator_code:org_t)
  • TITAN Investigators

Sammanhörande titlar

  • Ingår i:New England Journal of Medicine381:1, s. 13-240028-4793

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy